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Introduction: Newly developed antineoplastic drugs have resulted in improvements in morbidity and mortality
from many forms of cancers. However, some of these new chemotherapeutic agents have potentially lethal side
effects, which are now being exposed with their widespread use. Gemcitabine is a nucleoside analog, which is a
commonly used agent for various solid organ malignancies. Phase 1 and 2 trials with gemcitabine did not show
significant risk for cardiotoxicity; however, with its widespread clinical use over the last decade, a few cases of
cardiotoxicity related to gemcitabine use have been reported. Cardiomyopathy after the use of gemcitabine
monotherapy is extremely rare; and only one such case has been reported in detail previously.
Case presentation: We report a case of a 56-year-old African American man with pancreatic cancer who presented
with signs and symptoms of congestive heart failure after being treated with gemcitabine for two cycles (six doses).
A two-dimensional echocardiography showed left ventricular ejection fraction of 15 to 20 percent with global
hypokinesia. With the absence of significant risk factors for coronary artery disease and a strong temporal relationship
with the initiation of chemotherapy, it was concluded that our patient’s cardiomyopathy was related to the use of
gemcitabine. Gemcitabine was discontinued and our patient responded well to standard heart failure therapy. Two
months later, a repeat echocardiogram showed significant improvements in left ventricular systolic function.
Conclusions: Gemcitabine should be considered as a potential cause of cardiomyopathy in patients receiving
chemotherapy with this drug. We need further studies to look into potential mechanisms and treatments of
gemcitabine-induced cardiac dysfunction.
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Anticancer therapy has emerged tremendously over the
last few years. Newly available drugs and protocols have
resulted in improvements in morbidity and mortality
from many forms of cancers. However, these new antineo-
plastic drugs and protocols are not without potentially
lethal side effects. It is therefore very important to re-
cognize serious toxicities associated with some of these
medications, so appropriate measures can be taken to
avoid and manage such problems.
Gemcitabine is a nucleoside analog and a pyrimidine
antimetabolite that inhibits deoxyribonucleic acid (DNA)
synthesis by inhibition of DNA polymerase and ribonucle-
otide reductase [1]. It is a commonly used antineoplastic* Correspondence: docfahadkhan@yahoo.com
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pancreatic, ovarian, breast, bladder and non-small cell
lung cancers [2-7]. The Gastrointestinal Tumor Study
Group Phase III trial has shown promising results and has
led to the adoption of adjuvant chemoradiotherapy with
gemcitabine as the standard of care for advanced pancrea-
tic cancer [6].
Gemcitabine is generally well tolerated and is consi-
dered relatively safe as compared to many other chemo-
therapeutic agents. Its most common toxicities include
myelosuppression, changes in gastrointestinal function
(nausea, vomiting and diarrhea) and abnormalities in
liver and renal function tests [8].
Phase 1 and 2 studies with gemcitabine did not show
significant risk for cardiotoxicity, however, with its wide-
spread clinical use over the last decade, a few cases of
acute myocardial infarction (AMI) and arrhythmias asso-
ciated with gemcitabine use have been reported. Here,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer who developed dilated cardiomyopathy after be-
ing treated with gemcitabine.
Case presentation
A 56-year-old African American man who initially pre-
sented with diarrhea, weight loss and painless jaundice,
was subsequently found to have adenocarcinoma of the
head of pancreas. An initial workup revealed localized
cancer with no evidence of distant metastases. He then
underwent pancreaticoduodenectomy with complete sur-
gical resection of a 5cm moderately differentiated pan-
creatic adenocarcinoma. Although our patient underwent
complete surgical resection, a pathological examination
revealed a neoplastic invasion of the resected adjacent
organs, and one out of the seven resected lymph nodes
contained cancer (T3N1M0). At that point, the oncology
department recommended to proceed with adjuvant che-
motherapy with gemcitabine (1000mg/m2 IV on days 1, 8,
15 on a 28-day cycle for six cycles) to try to reduce the
likelihood of recurrence.
However, after completing two cycles (a total of six
doses) of chemotherapy, he presented to the emergency
department with worsening exertional dyspnea, three-
pillow orthopnea, paroxysmal nocturnal dyspnea and
fatigue. His physical examination revealed an elevated
jugular venous pressure (JVP) (10cm above the sternal
angle), bibasilar rales and +2 pitting edema of both lower
extremities. Cardiac auscultation revealed a gallop rhythm
with an S3 and a grade 3 holosystolic murmur over pre-
cordium. A chest X-ray showed cardiomegaly with mild to
moderate-sized right-sided pleural effusion. It was thought
that his presentation was consistent with fluid overload
secondary to congestive heart failure (CHF) and he was
started on intravenous (IV) furosemide with partial im-
provement in his symptoms.
The next day, a two-dimensional echocardiography (2D
Echo) was performed, which showed left ventricular ejec-
tion fraction (LVEF) of 15 to 20 percent with global hypo-
kinesia along with moderate mitral regurgitation. Given
the findings of 2D Echo and the absence of significant
risk factors for coronary artery disease (CAD) and ische-
mic cardiomyopathy (CMP), it was concluded that our
patient’s CMP was related to the recent use of gemcita-
bine. Our patient was then started on carvedilol and an
angiotensin-converting enzyme inhibitor in addition to
diuretics and he was discharged from the hospital two
days later in a euvolemic state.
At that point, the cardiology department recommen-
ded stopping further chemotherapy with gemcitabine.
The oncology department advised further testing to rule
out ischemia as a cause of CMP as, in their opinion,
chemotherapy with gemcitabine was the only option to
reduce the risk of recurrence in this patient. Two weekslater, our patient underwent myocardial perfusion ima-
ging (MPI), which showed a fixed small- to moderate-
sized inferior wall defect without any evidence of active
ischemia. The ejection fraction (EF) on MPI was calcula-
ted to be around 17 to 20 percent with severe global hy-
pokinesia. Our patient was continued on standard heart
failure therapy with one more admission to the hospital
for CHF exacerbation about two months later. He res-
ponded well to IV furosemide and adjustment of heart
failure therapy. A 2D Echo was repeated a few months
later and it showed improvement in systolic function
with an LVEF of 40 percent.
Due to his poor functional status and underlying CMP,
further gemcitabine chemotherapy was stopped. Later, our
patient developed a recurrence of his pancreatic cancer;
he refused further chemotherapy and decided to proceed
with palliative care.
Although the exact etiology of our patient’s dilated car-
diomyopathy remains unclear, gemcitabine remains the
most likely culprit. The temporal relationship of his symp-
toms to the initiation of gemcitabine chemotherapy; the
lack of risk factors for ischemic CMP and prior history of
CAD, finding of global hypokinesia on 2D Echo, absence
of ischemia on MPI; and improvement in his systolic func-
tion after discontinuation of gemcitabine were all consis-
tent with gemcitabine-induced cardiomyopathy.
Discussion
Gemcitabine is generally not considered as one of the
cardiotoxic agents, and its cardiotoxicity has been very
rarely reported in the literature. An overview of phase 1
trials of gemcitabine therapy revealed cardiac arrhyth-
mias in 0.7 to 1.4 percent of the patients, significant re-
duction in LVEF in 0.2 percent of the patients and the
development of exudative pericarditis in 0.2 percent of
the patients [9].
Similarly, phase 2 trials of gemcitabine monotherapy
did not show evidence of significant cardiotoxicity. To
evaluate overall safety of gemcitabine, Aapro et al. re-
viewed 22 phase 2 clinical trials (a total of 979 patients)
and found very low incidence of AMI (0.5 percent),
CMP (0.4 percent), arrhythmias (0.2 percent) and only
one case of mild pericarditis [8]. Among the cardiomyop-
athy cases, one patient had World Health Organization
(WHO) grade 4 toxicity indicating symptomatic cardiac
dysfunction not responding to conventional therapy. The
other three cases of CHF had WHO grade 3 toxicity, man-
ifesting as symptomatic systolic dysfunction, which res-
ponded to therapy [8]. Since the publication of the above
mentioned review, we could find two additional cases of
heart failure [10,11], four cases of AMI [10,12-14] and
one case of supraventricular tachycardia (SVT) [15] in
phase 2 gemcitabine trials [Table 1]. In a recent re-
view of the French PharmacoVigilance Database (FPVD),
Table 1 Case reports of cardiotoxicity with gemcitabine monotherapy




Side effect History of CAD Timing Outcome Probability
Ozturk et al. [17] 59F with metastatic
leiomyosarcoma
900mg/m2 8 days Coronary
vasospasm
Yes 30 minutes after infusion Survived. Gemcitabine
therapy stopped
Strong
Bdair et al. [18] 43F with metastatic NSCLC 1000mg/m2 7 weeks NSTEMI VT Yes 3 days after infusion Survived. Gemcitabine
therapy stopped
Weak
Kalapura et al. [19] 54M with metastatic
pancreatic cancer
1900mg 5th cycle NSTEMI No CAD, no
risk factors
6 hours after infusion Survived. Recurrent
symptoms with 7th cycle
Strong
Tayer-Shifman et al. [20] 67F with metastatic ductal
carcinoma of breast
1000-1400mg/m2 3rd cycle SVT/AVNRT No CAD, no
risk factors
Hours after infusion Survived. Gemcitabine
therapy stopped
Strong
Santini et al. [21] 78M with pancreatic
adenocarcinoma
NK 1st cycle AF History of AF
in the past
18-22 hours after the infusion Survived 6 total episodes
of AF 18-22 hours after the
infusion
Strong
Ferrari et al. [22] 72F with metastatic lung
adenocarcinoma
1200mg/m2 1st cycle AF No history of AF 18 hours after the infusion Survived 3 total episodes
of AF each after 18 hours
of infusion
Strong
Ferrari et al. [22] 73F with NSCLC 1200mg/m2 3rd cycle AF No history of AF 12 hours after the infusion Survived. Gemcitabine
stopped
Strong
Tavil et al. [23] 65M with NSCLC 1200mg/m2 2nd cycle AF No history of AF 7 hours after the infusion Gemcitabine stopped Strong
Ciotti et al. [24] 70M with metastatic
pancreatic adenocarcinoma
NK 1st cycle AF No history of AF 6 days after the infusion AF recurred with further
therapy
Strong






HF NK 2 years Gemcitabine stopped Weak




CMP/HF No prior history
of CHF/CAD
2 months Gemcitabine stopped,
partial recovery
Strong
CAD, coronary artery disease; F, female; NSCLC, non-small cell lung cancer; NSTEMI, non-ST elevation myocardial infarction; VT, ventricular tachycardia; M, male; SVT, supraventricular tachycardia; AVNRT, AV nodal
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tween dilated cardiomyopathy and chemotherapy with
gemcitabine [16].
Based on the review of medical literature, cardiotoxi-
city of gemcitabine can be divided into acute toxicities
and chronic toxicities.
Acute toxicities include arrhythmias and myocardial
ischemia or infarction. In almost all the cases, AMI de-
veloped within few hours to a couple of days after ge-
mcitabine infusion. The longest time interval between
gemcitabine infusion and the development of AMI was
reported to be six days, however in that case, the associ-
ation of the AMI to gemcitabine therapy was weak. The
exact reasons of gemcitabine-induced acute coronary
syndrome are not clear, however, authors have speculated
a direct endothelial injury resulting in coronary throm-
bosis or gemcitabine-induced vascular spasm as possible
underlying mechanisms. The evidence for prothrombotic
and procoagulant effects of gemcitabine comes from sev-
eral reports of occurrence of vascular events (like throm-
botic microangiopathies, strokes, visceral infractions and
vasculitides) in association with gemcitabine infusion [26].
Furthermore, in one other study of gemcitabine mono-
therapy for cutaneous T-cell lymphoma, authors noticed
higher incidence of thrombosis and vascular events in pa-
tients treated with gemcitabine [10]. Vasospasm was pro-
posed as a cause of chest pain and new-onset left bundle
branch block in a patient who developed these symptoms
during gemcitabine infusion. Vasospasm then resolved
within 10 minutes of antianginal therapy and serological
markers for myocardial damage remained negative [17].
Interestingly, all the patients who developed AMI related
to gemcitabine therapy had pre-existing CAD. Two of
these patients were already on appropriate antianginal
medications before they experienced gemcitabine-related
myocardial ischemia [17,18]. In another patient with a
previous episode of gemcitabine-induced myocardial is-
chemia, the next gemcitabine infusion was started con-
comitantly with IV nitroglycerine and beta blockers [19].
However, despite these measures he continued to have
recurrent ischemic symptoms with further gemcitabine
treatments.
SVTs including atrial fibrillation (AF) have been rarely
reported as a manifestation of gemcitabine cardiotoxi-
city. In contrast to AMI, where most of the patients had
underlying CAD, only one of the patients who developed
AF related to gemcitabine infusion had previous history
of AF [21]. Almost all the SVT episodes developed six to
18 hours after the administration of gemcitabine infu-
sion. Based on this observation, some authors have argued
that direct myocardial toxicity from an active metabolite
of 2′,2′-difluorodeoxyuridine (which has a half-life of 18
to 24 hours) is likely responsible for these electrical distur-
bances [21,22]. With the exception of one patient whoremained in AF at the time of discharge [22], sinus rhythm
could be restored in all of the other patients. Patients who
underwent chemical cardioversion (amiodarone or pro-
pafenone) converted to sinus rhythm within two hours
of onset of AF. Those who were treated conservatively
with rate control strategy converted spontaneously to
sinus rhythm on the average two days after the presenta-
tion. Three patients suffered recurrent AF episodes with
further gemcitabine infusions [21,22,24], and two of
them had recurrence of AF despite being on prophylactic
antiarrhythmics [21,24].
CMP is among the frequently reported cardiotoxicity
for many chemotherapeutic agents like anthracyclines,
but it has been rarely encountered with gemcitabine mo-
notherapy. The cardiomyopathy seems to develop after a
few months to years of treatments with gemcitabine.
The exact mechanisms of myocardial damage, and the
total dose of gemcitabine required to induce myocardial
toxicity are unknown. Most of the patients in phase 1
and 2 clinical trials who developed gemcitabine-induced
CMP had underlying CAD. Although our patient did
not have known CAD or CAD risk factors, it is still pos-
sible that he had a prior silent event (a fixed inferior wall
defect on MPI). However, a fixed inferior wall defect did
not explain severely depressed left ventricular (LV) sys-
tolic function and global hypokinesia seen on 2D Echo.
Given the fact that his heart failure symptoms started
after the initiation of gemcitabine, we strongly suspected
gemcitabine cardiotoxicity as a cause of his CMP. This
argument is further affirmed by the fact that his LV sys-
tolic function improved significantly after the disconti-
nuation of gemcitabine and the initiation of appropriate
treatment.
Gemcitabine has also been implicated in the deve-
lopment of exudative pericardial effusions. Four cases
of symptomatic and hemodynamically significant peri-
cardial effusions requiring drainage were reported by
Vogl et al. [27]. All of these patients were exposed to
unblocked cardiac radiations in the past, and all these
patients had pericardial abnormalities seen on echocardi-
ography before the initiation of gemcitabine chemothe-
rapy. The authors concluded that gemcitabine therapy in
these patients resulted in radiation recall reaction, that is,
gemcitabine recalled previous radiation-related inflamma-
tion in the pericardium.Conclusions
In our opinion, gemcitabine-induced cardiotoxicity should
be considered as a potential cause of arrhythmias, ische-
mia or cardiomyopathy in patients receiving chemothe-
rapy with this drug. We need further studies to look into
the potential mechanisms of gemcitabine-induced cardiac
dysfunction. In the case of toxicity, discontinuation of
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appropriate step in the management.
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